Contributing Factors to the Clinical and Economic Burden of Patients with Laboratory-Confirmed Carbapenem-Nonsusceptible Gram-Negative Respiratory Infections.

McCann, Eilish; Sung, Anita H; Ye, Gang; Vankeepuram, Latha; Tabak, Ying P

McCann, Eilish; Sung, Anita H; Ye, Gang; Vankeepuram, Latha; Tabak, Ying P.

Afiliação

McCann E; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
Sung AH; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
Ye G; Digital Health, Medical Affairs, Becton, Dickinson and Company, Franklin Lakes, NJ, USA.
Vankeepuram L; Digital Health, Medical Affairs, Becton, Dickinson and Company, Franklin Lakes, NJ, USA.
Tabak YP; Digital Health, Medical Affairs, Becton, Dickinson and Company, Franklin Lakes, NJ, USA.

Infect Drug Resist ; 13: 761-771, 2020.

Article em En | MEDLINE | ID: mdl-32210590

Palavras-chave

carbapenem-nonsusceptible; cost; gram-negative; mortality; respiratory infection

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google